iBio (IBIO) versus Its Peers Head-To-Head Survey

iBio (NASDAQ:IBIO) is one of 451 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare iBio to related companies based on the strength of its earnings, analyst recommendations, profitability, dividends, risk, institutional ownership and valuation.

Profitability

This table compares iBio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-126.93%	-83.06%
iBio Competitors	-2,625.49%	-359.57%	-43.35%

Institutional & Insider Ownership

7.9% of iBio shares are owned by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for iBio and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1	0	0	1	2.50
iBio Competitors	4800	9965	16004	371	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 126.22%. Given iBio’s rivals higher probable upside, analysts plainly believe iBio has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares iBio and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
iBio	$400,000.00	-$18.38 million	-0.72
iBio Competitors	$440.95 million	-$69.10 million	-9.71

iBio’s rivals have higher revenue, but lower earnings than iBio. iBio is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

iBio has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, iBio’s rivals have a beta of 10.24, indicating that their average share price is 924% more volatile than the S&P 500.

Summary

iBio rivals beat iBio on 7 of the 13 factors compared.

About iBio

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.